Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several ...

In pulmonary hypertension, a combination of metabolic and mechanical dysfunction leads to irreversible vascular damage.

Systemic lupus erythematosus is associated with an increased risk for pulmonary manifestations, including ILD and pulmonary hypertension.

A recent publication in the International Journal of Cardiology, "Pulmonary artery denervation in pulmonary hypertension: A ...

Pulmonary arterial hypertension (PAH) is a rare form of pulmonary hypertension. It occurs because progressive vascular ...

Exclusive e-cigarette use is significantly associated with new cases of chronic obstructive pulmonary disease.

In April 2025, Actelion announced a study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the ...

A recent publication in the International Journal of Cardiology, Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary ...

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with WHO Group 1 PAH FC 3 or 4 at high risk of mortality.

A recent publication by the British Thoracic Society offers the first long-term analysis of the UK Idiopathic Pulmonary ...

Report Ocean’s latest analysis delves into the “Vietnam Pulmonary Arterial Hypertension Market” Report from 2024 to 2032, covering an array of market facets such as characteristics, size, growth, ...